Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review

被引:0
作者
Matera, Maria Gabriella [1 ]
Calzetta, Luigino [2 ]
Rinaldi, Barbara [1 ]
de Novellis, Vito [1 ]
Page, Clive P. [3 ]
Barnes, Peter J. [4 ]
Cazzola, Mario [5 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dept Expt Med, Unit Pharmacol, Naples, Italy
[2] Univ Parma, Dept Med & Surg, Resp Dis & Lung Funct Unit, Parma, Italy
[3] Kings Coll London, Inst Pharmaceut Sci, London, England
[4] Imperial Coll London, Natl Heart & Lung Inst, London, England
[5] Univ Roma Tor Vergata, Dept Expt Med, Unit Resp Med, Rome, Italy
关键词
COPD; animal models; emphysema; genetically modified models; inflammation models; large animal models for COPD; murine models of COPD; smoke-induced COPD models; NONHUMAN PRIMATE MODEL; CIGARETTE-SMOKE; MOUSE MODELS; MUCUS HYPERSECRETION; N-ACETYLCYSTEINE; CYSTIC-FIBROSIS; LUNG-DISEASE; GUINEA-PIG; EMPHYSEMA; COPD;
D O I
10.1080/17460441.2025.2466704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionThe use of laboratory animals is essential to understand the mechanisms underlying COPD and to discover and evaluate new drugs. However, the complex changes associated with the disease in humans are difficult to fully replicate in animal models.Areas coveredThis review examines the most recent literature on animal models of COPD and their implications for drug discovery and development.Expert opinionRecent advances in animal models include the introduction of transgenic mice with an increased propensity to develop COPD-associated features, such as emphysema, and animals exposed to relevant environmental agents other than cigarette smoke, in particular biomass smoke and other air pollutants. Other animal species, including zebrafish, pigs, ferrets and non-human primates, are also increasingly being used to gain insights into human COPD. Furthermore, three-dimensional organoids and humanized mouse models are emerging as technologies for evaluating novel therapeutics in more human-like models. However, despite these advances, no model has yet fully captured the heterogeneity and progression of COPD as observed in humans. Therefore, further research is needed to develop improved models incorporating humanized elements in experimental animals, that may better predict therapeutic responses in clinic settings and accelerate the development of new treatments for this debilitating disease.
引用
收藏
页码:337 / 356
页数:20
相关论文
共 165 条
  • [1] Global strategy for prevention, diagnosis and management of COPD: 2025 report
  • [2] Barnes P.J., Burney P.G., Silverman E.K., Et al., Chronic obstructive pulmonary disease, Nat Rev Dis Primers, 1, 1, (2015)
  • [3] Matera M.G., Cazzola M., Page C., Prospects for COPD treatment, Curr Opin Pharmacol, 56, pp. 74-84, (2021)
  • [4] Chen S., Small M., Lindner L., Et al., Symptomatic burden of COPD for patients receiving dual or triple therapy, Int J Chron Obstruct Pulmon Dis, 13, pp. 1365-1376, (2018)
  • [5] Matera M.G., Page C.P., Calzetta L., Et al., Pharmacology and therapeutics of bronchodilators revisited, Pharmacol Rev, 72, 1, pp. 218-252, (2020)
  • [6] Cazzola M., Rogliani P., Matera M.G., The future of bronchodilation: looking for new classes of bronchodilators, Eur Respir Rev, 28, 154, (2019)
  • [7] Cazzola M., Rogliani P., Matera M.G., The future of bronchodilators in COPD and asthma, Arch Bronconeumol, 58, 2, pp. 107-108, (2022)
  • [8] Cazzola M., Hanania N.A., Page C.P., Et al., Novel anti-inflammatory approaches to COPD, Int J Chron Obstruct Pulmon Dis, 18, pp. 1333-1352, (2023)
  • [9] Li C.L., Liu S.F., Exploring molecular mechanisms and biomarkers in COPD: an overview of current advancements and perspectives, Int J Mol Sci, 25, 13, (2024)
  • [10] Whittaker H.R., Jarvis D., Sheikh M.R., Et al., Inhaled corticosteroids and FEV<sub>1</sub> decline in chronic obstructive pulmonary disease: a systematic review, Respir Res, 20, 1, (2019)